JUNS
JUPITER NEUROSCIENCES, INC.
Key Financials
Operating Income
$-8908721
↓ 188.2%
Revenue
$21796
N/A
Total Assets
$5.6M
↓ 10.3%
Shareholders' Equity
$-1831852.00
↓ 143.9%
Total Liabilities
$7.4M
↑ 264.3%
Gross Profit
$17565
N/A
Net Income
$-8644897
↓ 254.4%
EPS (Diluted)
$-0.25
↓ 212.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-3 | 9/25/2026 | View on SEC |
| SCHEDULE 13G | 9/22/2026 | View on SEC |
| D | 9/4/2026 | View on SEC |
| 8-K | 9/3/2026 | View on SEC |
| SCHEDULE 13G/A | 8/28/2026 | View on SEC |
| SCHEDULE 13G | 8/28/2026 | View on SEC |
| 8-K | 8/28/2026 | View on SEC |
| 8-K | 8/27/2026 | View on SEC |
| 8-K | 8/24/2026 | View on SEC |
| 8-K | 8/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JUNS |
| Company Name | JUPITER NEUROSCIENCES, INC. |
| CIK | 1679628 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (561) 406-6154 |